Investigational drug · Phase 2
ZSP1601
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Nonalcoholic Steatohepatitis (NASH).
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 19, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "ZSP1601"
First trial start
2023
Jun 3, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ZSP1601", any sponsor or status.
Conditions studied
As listed on its trial records.
- Nonalcoholic Steatohepatitis (NASH)
Approved drugs for the same conditions: MASH (fatty liver disease) · Infectious disease and vaccines · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "ZSP1601" as an intervention, largest first.
- A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)Pivotal-lookingActive, not recruiting
Guangdong Raynovent Biotech Co., LtdIndustry
NCT05692492 · 180 participants · Start Jun 3, 2023 · Primary completion Jun 16, 2026
Drug: ZSP1601; ZSP1601 and 1 more · For: Nonalcoholic Steatohepatitis (NASH)
Sites: Guangzhou, China
Guangdong Zhongsheng Pharmaceutical Co., Ltd.Industry
NCT03392779 · 94 participants · Start Jan 5, 2018 · Primary completion Dec 21, 2018
Drug: ZSP1601 25 mg; Placebo 25mg and 16 more · For: Nonalcoholic Steatohepatitis (NASH)
Sites: Changchun, China
- Tolerability, Efficacy, and PK of ZSP1601 in Patients With Non-Alcoholic Steatohepatitis (NASH)Completed
Guangdong Raynovent Biotech Co., LtdIndustry
NCT04140123 · 37 participants · Start Jun 23, 2020 · Primary completion Aug 3, 2021
Drug: ZSP1601; ZSP1601 Placebo · For: Non-Alcoholic Steatohepatitis (NASH)
Sites: Changchun, China
Newest research
PubMed records naming it or its code names, newest first.
- ZSP1601 is a non-selective phosphodiesterase inhibitor and a clinical drug candidate for the oral treatment of metabolic dysfunction-associated steatohepatitis.
Liu M, Liu Z, Leng Y, et al. · Biochem Biophys Res Commun 2026
- Pipeline of New Drug Treatment for Non-alcoholic Fatty Liver Disease/Metabolic Dysfunction-associated Steatotic Liver Disease.
Hu Y, Sun C, Chen Y, et al. · J Clin Transl Hepatol 2024
- Dose finding for ZSP1601 in patients with nonalcoholic steatohepatitis using population pharmacokinetics and exposure-response approach.
Li H, Hu Y, Yang Y, et al. · Eur J Pharm Sci 2024
- ZSP1601, a novel pan-phosphodiesterase inhibitor for the treatment of NAFLD, A randomized, placebo-controlled phase Ib/IIa trial.
Hu Y, Li H, Zhang H, et al. · Nat Commun 2023
- Safety, tolerability, and pharmacokinetics of the novel pan-phosphodiesterase inhibitor ZSP1601 in healthy subjects: a double-blinded, placebo-controlled first-in-human single-dose and multiple-dose escalation and food effect study.
Zhu X, Wu M, Wang H, et al. · Expert Opin Investig Drugs 2021
Also in development for Nonalcoholic Steatohepatitis (NASH)
- EfimosferminBOS-580Phase 37 trials
GSK · Non-alcoholic Fatty Liver Disease, Metabolic Dysfunction-associated Steatohepatitis, Liver Diseases, Alcoholic
- HTD1801Berberine UrsodeoxycholatePhase 34 trials
Shenzhen HighTide Biopharmaceutical Ltd. · T2DM (Type 2 Diabetes Mellitus), Nonalcoholic Steatohepatitis (NASH), Type 2 Diabetes
- pegargiminaseADI-PEG 20Phase 33 trials
Polaris Group · Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.